首页> 外文期刊>Journal of Cardiovascular and Thoracic Research >Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up)
【24h】

Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up)

机译:用于不同退化的生物假体瓣膜的Edwards Sapien BioResthettic瓣膜的经变压表心阀与Edwards Sapien BioMoRoSthettic瓣膜(第一届伊朗VIV报告中期跟进)

获取原文
           

摘要

Introduction After early successful experience with transcatheter aortic valve replacement (TAVR), concept of transcatheter implantation of a new valve within a failing bioprosthetic valve emerged. Valve-in-valve (ViV) implantation seems to be a simpler option for high risk surgical patients. Methods We performed five ViV procedures in different valve positions. We included patients with failing bioprosthetic valves with high surgical risk due to concomitant comorbidities. We performed 2 transapical ViV procedures for failing mitral bioprosthetic valves, 1 transfemoral procedure for failing pulmonary valve and 2 transfemoral ViV implantation for failing tricuspid bioprosthetic valves. Results The procedures were successfully completed in all 5 cases with initial excellent fluoroscopic and echocardiographic verification. There was no valve embolization or paravalvular leakage in any of the cases. Transcatheter valve function was appropriate with echocardiography. Post procedural clinical adverse events like pleural effusion and transient ischemic attack were managed successfully. In midterm follow up all cases remained in appropriate functional class except from the transcatheter pulmonary valve which became moderately stenotic and regurgitant. Conclusion As the first Iranian all-comers case series with midterm follow up for ViV implantation, we had no mortality. Interestingly none of our patients had neurologic sequelae after the procedure. Midterm follow up for our patients was acceptable with good functional class and appropriate echocardiographic findings. Due to high surgical risk of the redo procedure after failing of a bioprosthetic valve especially in elderly patients with comorbidities, ViV implantation would be a good alternative to surgery for this high risk group.
机译:早期成功经验后介绍经沟管主动脉瓣更换(TAVR),经截面植入故障发生的生物假阀内的新阀的概念。阀门内(VIV)植入似乎是高风险手术患者的更简单选择。方法我们在不同的阀门位置进行了五个VIV程序。由于伴随的同血症,我们包括患有失败的生物假体瓣膜,具有高手术风险。我们进行了2例转型VIV程序,用于失败二尖瓣生物体瓣膜,1用于失败的肺瓣膜和2用于失效的TRICUSPID生物假体瓣膜的转熔血液植入程序。结果所有5例初始优异的荧光透视和超声心动图核查成功完成了该程序。在任何情况下都没有瓣膜栓塞或瓣膜渗漏。转截管阀功能适合超声心动图。胸腔积液和瞬态缺血攻击等程序临床不良事件得到成功管理。在Midterm后续后,所有案例都仍处于适当的功能类中,除了从转导管肺瓣膜变得中间狭窄和反刍。结论作为第一批伊朗全能案例系列与中期后续的VIV植入,我们没有死亡率。有趣的是,我们的患者均未在手术后患有神经系统后遗症。中期随访我们的患者是可以接受的,良好的功能阶级和适当的超声心动图发现。由于在未发生生物假体瓣膜未发生生物假体瓣膜后的重做手术的高手术风险,尤其是老年人的患者,VIV植入将是这种高风险群体的替代手术。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号